EPISODE · Jun 16, 2022 · 12 MIN
Treatment of Advanced Urothelial Carcinoma – A Discussion of EV-301
from IMPACT Medicom · host IMPACT Medicom
Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. Our Guest:Our guest for this episode is Dr Nimira Alimohamed, Medical Oncologist and Clinical Associate Professor of Medicine at the University of Calgary and Medical Oncologist at the Tom Baker Cancer Centre in Calgary, Alberta. This podcast episode was sponsored by Seagen Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Embed this episode
What this episode covers
Welcome to our podcast episode on the treatment of urothelial carcinoma. In this episode, hosted by Anna Christofides, we discuss updated results of the Phase 3 EV-301 trial, presented at ASCO 2022, that examined the efficacy and safety of Enfortumab Vedotin, or EV, versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma. Our Guest: Our guest for this episode is Dr Nimira Alimohamed, Medical Oncologist and Clinical Associate Pr...
NOW PLAYING
Treatment of Advanced Urothelial Carcinoma – A Discussion of EV-301
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.